A5101531161- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Animal Genetics and Reproduction
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- CRISPR and Genetic Engineering
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Intracranial Aneurysms: Treatment and Complications
- PI3K/AKT/mTOR signaling in cancer
- Virus-based gene therapy research
- Neuroscience and Neuropharmacology Research
- Cytokine Signaling Pathways and Interactions
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Synthesis and biological activity
- Pancreatic and Hepatic Oncology Research
- Epilepsy research and treatment
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Vascular Malformations Diagnosis and Treatment
Shikoku Cancer Center
2021-2024
Ehime University
2021-2024
Okayama University
2012-2023
Okayama University Hospital
2012-2023
Osaka University
2023
Kawasaki Medical School
2013
Kawasaki Hospital
2013
Sumitomo Besshi Hospital
2012-2013
Okayama Shoka University
2011-2013
Hamamatsu University
2011
Exogenous microglia pass through the blood—brain barrier and migrate to ischemic hippocampal lesions when injected into circulation. We investigated effect of exogenous on CA1 pyramidal neurons. Microglia were isolated from neonatal mixed brain cultures, labeled with fluorescent dye PKH26, subclavian artery Mongolian gerbils subjected ischemia reperfusion neuronal injury. PKH26-labeled migrated lesion, resulting in increased numbers surviving neurons compared control animals, even 24 h after...
Small cell lung cancer (SCLC) accounts for about 15% of all cancers. The prognosis SCLC patients is devastating and no biologically targeted therapeutics are active in this tumor type. To develop a framework development specific SCLC-targeted drugs we conducted combined genomic pharmacological vulnerability screen lines. We show that lines capture the landscape primary tumors provide genetic predictors activity clinically relevant inhibitors by screening 267 compounds across 44 these Aurora...
Crizotinib is the standard of care for advanced non-small cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase (ALK) fusion gene, but resistance invariably develops. Unlike crizotinib, alectinib a selective ALK tyrosine inhibitor (TKI) with more potent antitumor effects and favorable toxicity profile, even in crizotinib-resistant cases. However, acquired to alectinib, as other TKIs, remains limitation its efficacy. Therefore, we investigated mechanisms by which human NSCLC...
Abstract Introduction Immune checkpoint inhibitors (ICIs) have demonstrated long survival for the treatment of advanced non-small cell lung cancer (NSCLC). However, effect and safety ICI rechallenge not been fully evaluated. The aim this study was to investigate efficacy in NSCLC patients. Methods We defined ‘rechallenge’ as re-administration ICIs patients who were previously treated with discontinued any reason, received subsequent chemotherapy. retrospectively analyzed histories 434 from...
Abstract The prognosis of non‐small‐cell lung cancer (NSCLC) patients with interstitial disease (ILD) is poor, and 5%‐20% those receiving chemotherapy experience ILD exacerbation. To evaluate the safety efficacy nab‐paclitaxel plus carboplatin for NSCLC ILD, we undertook a multicenter phase II study. Chemotherapy‐naïve advanced mild or moderate received (100 mg/m 2 , days 1, 8, 15) (area under curve = 6, day 1) every 3 weeks 4 cycles (maximum, 6 cycles). Interstitial diseases were diagnosed...
Abstract Purpose This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD). Methods multicenter retrospective collected data consecutive advanced NSCLC patients who underwent EGFR-TKI ILD. Results Fifty-eight were registered. The grades initial TKI-induced ILD grade 1 to 4. TKIs used for erlotinib 15 patients, osimertinib 15, gefitinib 14,...
Abstract An irreversible ErbB family blocker is expected to inhibit tumors with activating epidermal growth factor receptor (EGFR) mutations more strongly than reversible EGFR tyrosine kinase inhibitors and overcome acquired resistance the T790M secondary mutation. Eleven-week-old transgenic mice Egfr exon 19 deletion mutation were treated afatinib, gefitinib, or vehicle for 4 weeks. All sacrificed at 15 weeks of age, number superficial left lung a long axis exceeding 1 mm was counted. The...
Tumors are presumed to contain a small population of cancer stem cells (CSCs) that initiate tumor growth and promote spreading. Multidrug resistance in CSCs is thought allow the evade conventional therapy. This study focused on expression CD133 CD87 because putative marker some cancers including lung, associated with stem-cell-like property small-cell lung (SCLC). Six SCLC cell lines were used. The levels analyzed by real-time quantitative reverse transcription-polymerase chain reaction flow...
Abstract Molecular agents targeting the epidermal growth factor receptor ( EGFR )‐, anaplastic lymphoma kinase ALK )‐ or c‐ ros oncogene 1 ROS1 ) alterations have revolutionized treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, emergence acquired resistance remains a significant challenge, limiting wider clinical success these molecular targeted therapies. In this study, we investigated efficacy various agents, including erlotinib, alectinib, and crizotinib, combined...
As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer harboring EGFR T790M mutation; however, acquired resistance inevitably develops. Therefore, next-generation strategy warranted in osimertinib era. We investigated mechanism of to novel EGFR-TKI, naquotinib, goal developing strategy. established multiple naquotinib-resistant lines or osimertinib-resistant cells, two...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations. However, even in patients an initial dramatic response to a drug, acquired resistance develops after 6-12 months. A secondary mutation of T790M amplification the MET gene account this resistance; however, mechanism(s) approximately 30% cases remain unknown. We established erlotinib-resistant line named PC-9/ER3 that...
Although osimertinib is a promising therapeutic agent for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the incidence of pneumonitis particularly high among Japanese patients receiving drug. Furthermore, safety and efficacy subsequent anticancer treatments, including EGFR-tyrosine kinase inhibitor (TKI) rechallenge, which are to be administered after recovery, remain unclear. This study investigated EGFR-TKI rechallenge in who experienced first-line...
Abstract Aminopeptidase activities of cell free extract from 11 strains Streptococcus lactis and cremoris , used as starter bacteria in cheese manufacture, were determined with 54 synthetic substrates. Based on these aminopeptidase profiles, divided into three groups by cluster analysis. Enzymes involved representative each ( 527, ML-14, nTR) separated partly diethylaminoethyl-cellulose chromatography compared for enzyme's optimum pH the effect various metal ions chemicals. These have at...
Non-small-cell lung cancers with epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase inhibitors (TKIs); however, unlike cytotoxic agents, it is generally accepted that minimal doses of drugs inhibiting target molecules sufficient when molecular-targeted including EGFR-TKIs, used. Thus, any utility higher remains unclear. We compared low-dose (15 mg/kg) gefitinib therapy high-dose (50 using an EGFR-mutated cancer xenograft model. Both induced tumor...
Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report case PPC that showed rapid response to nivolumab. The patient, whose multiple tumors had progressed aggressively, was treated with nivolumab, an anti-programmed death-1 (PD-1) antibody. dramatically shrank after one cycle were positive for programmed death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1...
The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) induction coupled with standard concurrent chemoradiotherapy (CRT) is unclear in unresectable, stage III, EGFR-mutant non-small-cell lung cancer (NSCLC). Therefore, a phase II trial was conducted to evaluate the efficacy and safety gefitinib followed by CRT this disease setting.Patients EGFR-mutant, III NSCLC were administered monotherapy (250 mg/day) for 8 weeks. Subsequently, patients without progression...
Fragments containing 5' flanking regions of four bovine milk protein genes--alpha lactalbumin (b alpha LA), S1 casein S1CN), beta CN), kappa CN)--and mouse whey acidic (mWAP) gene were prepared by PCR and ligated to human growth hormone (hGH) gene. These recombinant DNAs microinjected into rat embryos produce transgenic rats, the functions direct secretion hGH in tested. Although was obtained only 5 19 mWAP/hGH lines, more than two-thirds rats carrying other produced milk. More 80% lactated...
Abstract We previously reported on a family with hereditary lung cancer, in which germline mutation the transmembrane domain (G660D) of avian erythroblastic leukemia viral oncogene homolog 2 (erb-b2 receptor tyrosine kinase 2) (ERBB2; human epidermal growth factor [HER2]) seemed to be responsible for cancer predisposition. Although few data are available treatment, anti-ERBB2 therapeutic agents may effective ERBB2-mutant cancers. The familial patient one authors’ institutes developed bone...